DOC · 10-Q · 2026Q3

HEALTHPEAK PROPERTIES, INC.

Filed 2026-11-03 · Real Estate · View original filing on EDGAR

Everything DOC's SEC filings said, ranked

Ranked Events

• Financing Cash Flow TrendsImportance 77 · Surprise 82
  Net cash provided by financing activities increased $2.02 billion to $1.67 billion for the nine months ended September 30, 2026, compared with $353.4 million of net cash used in 2025. Inflows included Janus Living IPO…
• Investing Cash Flow and AcquisitionsImportance 77 · Surprise 82
  Net cash used in investing activities increased $1.95 billion to $2.58 billion for the nine months ended September 30, 2026. The increase primarily reflected higher cash used for real-estate acquisitions, including the…
• Transaction Cost TrendsImportance 71 · Surprise 82
  Transaction costs rose $7.3 million year over year to $9.7 million for the third quarter of 2026 and increased $24.9 million to $43.1 million for the first nine months. Third-quarter increases reflected investment…
• Net Income and ProfitabilityImportance 69 · Surprise 64
  For the three months ended September 30, 2026, net income applicable to common shares was $17.118 million, compared with a net loss of $117.256 million in the 2025 quarter, an improvement of $134.374 million. The…
• Brookfield Outpatient Medical Joint VentureImportance 65 · Surprise 60
  In July 2026, Healthpeak formed a joint venture with an affiliate of Brookfield Asset Management and contributed 86 outpatient medical buildings diversified across 11 states. Brookfield purchased a non-controlling 49%…
• Liquidity and Capital PositionImportance 61 · Surprise 32
  Material debt-related cash requirements declined $466 million to $9.4 billion at September 30, 2026, reflecting repayments of $102 million senior housing mortgage debt, $142 million outpatient medical mortgage debt,…
• Senior Housing NOI GrowthImportance 59 · Surprise 48
  For the three months ended September 30, 2026, Senior Housing Same-Store Adjusted NOI increased 25.9% to $31.9 million, and Total Portfolio Adjusted NOI increased to $53.7 million from $42.2 million. For the nine…
• Janus Living IPO and Follow-On OfferingImportance 59 · Surprise 60
  Janus Living completed its IPO on March 23, 2026, issuing 48.3 million Class A-1 shares for $966 million gross proceeds, less $65 million of underwriting fees. In connection with the formation transactions, Healthpeak…
• Acquisitions and DivestituresImportance 58 · Surprise 42
  In January 2026, Healthpeak acquired its joint venture partner’s 46.5% interest in SWF SH JV for $312 million and acquired two lab land parcels for net proceeds of $28 million. During the nine months ended September…
• Interest Rate ExposureImportance 54 · Surprise 40
  As of September 30, 2026, approximately 83% of Healthpeak’s consolidated debt was fixed rate, down from 95% a year earlier. Fixed-rate and variable-rate debt had weighted-average effective interest rates of 4.24% and…
• Income Tax Rate ChangesImportance 53 · Surprise 82
  Nine-month income tax expense decreased by $3.1 million, from $3.3 million in 2025 to $0.1 million in 2026. The decrease primarily reflected tax benefits from derecognizing deferred tax assets and liabilities after…
• Lab Segment NOI PerformanceImportance 49 · Surprise 32
  For the three months ended September 30, 2026, Lab Same-Store Adjusted NOI decreased 0.7% to $113.6 million, while Total Portfolio Adjusted NOI rose $2.8 million to $140.9 million. For the nine months, Same-Store…
• Outpatient Medical NOI PerformanceImportance 49 · Surprise 32
  For the three months ended September 30, 2026, outpatient medical Same-Store Adjusted NOI increased 3.1% to $173.2 million, while Total Portfolio Adjusted NOI fell $13.8 million to $184.3 million. Nine-month Same-Store…
• Interest Expense TrendsImportance 48 · Surprise 40
  Interest expense increased $7.1 million year over year to $83.9 million for the third quarter of 2026 and increased $38.9 million to $263.5 million for the first nine months. Higher commercial paper borrowings and the…
• Operating Cash Flow TrendsImportance 43 · Surprise 32
  Net cash provided by operating activities increased $18.6 million to $976.4 million for the nine months ended September 30, 2026, compared with $957.9 million in 2025. Growth reflected acquisitions, developments and…
• Development and Loan CommitmentsImportance 42 · Surprise 40
  Development, redevelopment, and Company-owned tenant-improvement commitments decreased $23 million to $199 million at September 30, 2026, mainly due to construction spending, partly offset by new redevelopment…
• Trade Policy and TariffsImportance 34 · Surprise 42
  Healthpeak identifies U.S. political-administration tariff actions and potential future tariff actions as a source of uncertainty affecting its business. The filing states that tariff actions, alongside higher…
• Development and Redevelopment PipelineImportance 32 · Surprise 24
  During the nine months ended September 30, 2026, Healthpeak placed two lab redevelopment projects with total project costs of $103 million in service, as well as portions of six lab redevelopments totaling $94 million…
• Share Repurchase ProgramImportance 28 · Surprise 42
  In April 2026, Healthpeak repurchased 5.95 million shares of common stock under its 2024 Share Repurchase Program. The shares were bought at a weighted average price of $16.81 each, for a total expenditure of $100…
• Occupancy and Leasing ActivityImportance 20 · Surprise 24
  Outpatient medical Adjusted NOI declined partly because of lower occupancy and dispositions, while development and redevelopment placements and new leasing activity provided partial offsets. Healthpeak owned 506…

Revenue by Product (in thousands)